Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) EPS (Weighted Average and Diluted) (2021 - 2025)

Krystal Biotech (KRYS) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with $1.7 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 11.11% to $1.7 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.85 through Dec 2025, up 128.33% year-over-year, with the annual reading at $6.84 for FY2025, 128.0% up from the prior year.
  • EPS (Weighted Average and Diluted) hit $1.7 in Q4 2025 for Krystal Biotech, down from $2.66 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.79 in Q3 2023 to a low of -$1.99 in Q1 2022.
  • Historically, EPS (Weighted Average and Diluted) has averaged $0.07 across 5 years, with a median of -$0.34 in 2021.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 168.92% in 2022 and later surged 3900.0% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.95 in 2021, then plummeted by 31.58% to -$1.25 in 2022, then soared by 124.8% to $0.31 in 2023, then surged by 393.55% to $1.53 in 2024, then grew by 11.11% to $1.7 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for KRYS at $1.7 in Q4 2025, $2.66 in Q3 2025, and $1.29 in Q2 2025.